Glucose-lowering agents and the patterns of risk for cancer: A study with the General Practice Research Database and secondary care data

Diabetologia

Volumn 55, Issue 3, 2012, Pages 654-665

  Van Staa, T P ^a,b   Patel, D ^a   Gallagher, A M ^a,b   De Bruin, M L ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cancer incidence rate; Diabetes mellitus; Insulin; Insulin glargine; Metformin; Sulfonylureas; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE DATABASE; SKIN CANCER; TREATMENT DURATION; UTERINE CERVIX CANCER; UTERUS CANCER;

AGED; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; NEOPLASMS; POISSON DISTRIBUTION; REGISTRIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84856698481     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2390-3     Document Type: Article

References (32)

1. LG Hemkens U Grouven R Bender, et al. 2009 Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study Diabetologia 52 1732 1744 19565214 10.1007/s00125-009-1418-4 1:CAS:528:DC%2BD1MXpsFyrsL0%3D
2. JM Jonasson R Ljung M Talbäck B Haglund S Gudbjornsdottir G Steineck 2009 Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden Diabetologia 52 1745 1754 19588120 10.1007/s00125-009-1444-2 1:STN:280:DC%2BD1MrktlygtQ%3D%3D
3. CJ Currie CD Poole EA Gale 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 1766 1777 19572116 10.1007/s00125-009-1440-6 1:CAS:528:DC%2BD1MXpsFyrsLo%3D
4. HM Colhoun SDRN Epidemiology Group 2009 Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group Diabetologia 52 1755 1765 19603149 10.1007/s00125-009-1453-1 1:STN:280:DC%2BD1Mrktl2kuw%3D%3D Erratum 52: 2469
5. U Smith EAM Gale 2009 Does diabetes therapy influence the risk of cancer? Diabetologia 52 1699 1708 19597799 10.1007/s00125-009-1441-5 1:STN:280:DC%2BD1Mrktl2mtQ%3D%3D
6. SJ Pocock L Smeeth 2009 Insulin glargine and malignancy: an unwarranted alarm Lancet 374 511 513 19616841 10.1016/S0140-6736(09)61307-6
7. F de Vries CS de Vries C Cooper HGM Leufkens TP van Staa 2006 Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database Int J Epidemiol 35 1301 1308 17053011 10.1093/ije/dyl147
8. Parkinson J, Davis S, van Staa TP (2007) The General Practice Research (GPRD) Database: now and the future. In: Mann R (ed) Pharmacovigilance. Wiley, Chichester, pp 341-348
9. E Herrett SL Thomas WM Schoonen L Smeeth AJ Hall 2010 Validation and validity of diagnoses in the General Practice Research Database: a systematic review Br J Clin Pharmacol 69 4 14 20078607 10.1111/j.1365-2125.2009.03537.x 1:CAS:528:DC%2BC3cXhvFSltLk%3D
10. WA Ray 2003 Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 915 920 14585769 10.1093/aje/kwg231
11. H Ramlau-Hansen 1983 Smoothing counting process intensities by means of kernel functional Ann Statist 11 453 466 10.1214/aos/1176346152
12. CJ Wotton DG Yeates MJ Goldacre 2011 Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies Diabetologia 54 527 534 21116605 10.1007/s00125-010-1987-2 1:STN:280: DC%2BC3M7mvFCnsg%3D%3D
13. P Vigneri F Frasca L Sciacca G Pandini R Vigneri 2009 Diabetes and cancer Endocr Relat Cancer 16 1103 1123 19620249 10.1677/ERC-09-0087 1:CAS:528:DC%2BC3cXhtFOgu7w%3D
14. JA Johnson SL Bowker 2011 Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials Diabetologia 54 25 31 20959956 10.1007/s00125-010-1933-3 1:CAS:528:DC%2BC3cXhsFWqtLfI
15. G Stefansdottir S Zoungas J Chalmers, et al. 2011 Intensive glucose control and risk of cancer in patients with type 2 diabetes Diabetologia 54 1608 1614 21509444 10.1007/s00125-011-2104-x 1:STN:280:DC%2BC3MrosVymtQ%3D%3D
16. YX Yang S Hennessy JD Lewis 2004 Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 127 1044 1050 15480982 10.1053/j.gastro.2004.07.011 1:CAS:528:DC%2BD2cXpsVOitrg%3D
17. JMM Evans LA Donnelly AM Emslie-Smith DR Alessi AD Morris 2005 Metformin and reduced risk of cancer in diabetic patients BMJ 330 1304 1305 15849206 10.1136/bmj.38415.708634.F7
18. SL Bowker SR Majumdar P Veugelers JA Johnson 2006 Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 254 258 16443869 10.2337/diacare.29.02.06.dc05-1558
19. R Govindarajan L Ratnasinghe DL Simmons, et al. 2007 Thiazolidinediones and risk of lung, prostate, and colon cancer in patients with diabetes J Clin Oncol 25 1476 1481 17442990 10.1200/JCO.2006.07.2777 1:CAS:528: DC%2BD2sXlsVyntbs%3D
20. C Koro S Barrett N Qizilbash 2007 Cancer risks in thiazolidinedione users compared to other anti-diabetic agents Pharmacoepidemiol Drug Saf 16 485 492 17192841 10.1002/pds.1352 1:CAS:528:DC%2BD2sXms1Oltrg%3D
21. M Monami D Balzi C Lamanna, et al. 2007 Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality Diabetes-Metab Res 23 479 484 10.1002/dmrr.736 1:STN:280:DC%2BD2srhtlSjug%3D%3D
22. M Monami C Lamanna L Pala, et al. 2008 Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients: a retrospective cohort study Exp Clin Endocrinol Diabetes 116 184 189 18273755 10.1055/s-2007-992157 1:CAS:528:DC%2BD1cXlsVWjs78%3D
23. JD Lewis AM Capra NS Achacoso, et al. 2008 Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus Gastroenterology 135 1914 1923 18930061 10.1053/j.gastro.2008.09.004 1:CAS:528:DC%2BD1MXht1ersbc%3D
24. YW Chung DS Han KH Park CS Eun KS Yoo CK Park 2008 Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea Dis Colon Rectum 51 593 597 18219529 10.1007/s10350-007-9184-1
25. TJ Murtola TL Tammela J Lahtela A Auvinen 2008 Antidiabetic medication and prostate cancer risk: a population-based case-control study Am J Epidemiol 168 925 931 18700234 10.1093/aje/kwn190
26. G Libby LA Donnelly PT Donnan DR Alessi AD Morris JMM Evans 2009 New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 1620 1625 19564453 10.2337/dc08-2175 1:CAS:528:DC%2BD1MXht1agtrzE
27. M Bodmer C Meier S Krähenbühl SS Jick CR Meier 2010 Long-term metformin use is associated with decreased risk of breast cancer Diabetes Care 33 1304 1308 20299480 10.2337/dc09-1791 1:CAS:528:DC%2BC3cXotFKhs7g%3D
28. E Mannucci M Monami D Balzi, et al. 2010 Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients Diabetes Care 33 1997 2003 20551014 10.2337/dc10-0476 1:CAS:528: DC%2BC3cXht1OmurnO
29. DM Baur J Klotsche OP Hamnvik, et al. 2011 Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort Metabolism 60 1363 1371 21081242 10.1016/j.metabol.2010.09.012 1:CAS:528:DC%2BC3MXhtFyns7nF
30. M Monami C Colombi D Balzi, et al. 2011 Metformin and cancer occurrence in insulin-treated type 2 diabetic patients Diabetes Care 34 129 131 20980415 10.2337/dc10-1287
31. JL Bosco S Antonsen HT Sørensen L Pedersen TL Lash 2011 Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark Cancer Epidemiol Biomark Prev 20 101 111 10.1158/1055-9965. EPI-10-0817 1:CAS:528:DC%2BC3MXhvVClsw%3D%3D
32. JE Rossouw GL Anderson R Prentice Writing Group for the Women's Health Initiative Investigators, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333 12117397 10.1001/jama.288.3.321 1:CAS:528:DC%2BD38Xltlegs7k%3D